Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-17 (canceled)

18 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~or salt of claim 1 to the animal~~of the formula (I):



(I)

wherein: X is $-CHR_5-$, $-CHR_5$-alkyl-, or $-CHR_5$-alkenyl-;

R_1 is selected from the group consisting of:

$-R_4—NR_3—SO_2—R_6—$alkyl;

$-R_4—NR_3—SO_2—R_6—$alkenyl;

$-R_4–NR_3–SO_2–R_6–$aryl;

$-R_4–NR_3–SO_2–R_6–$heteroaryl;

$-R_4–NR_3–SO_2–R_6–$heterocyclyl;

$-R_4—NR_3—SO_2—R_7$;

$-R_4$-NR_3-SO_2-NR_5-R_6-alkyl;

$-R_4$-NR_3-SO_2-NR_5-R_6-alkenyl;

$-R_4$-NR_3-SO_2-NR_5-R_6-aryl;

$-R_4$-NR_3-SO_2-NR_5-R_6-heteroaryl;

$-R_4$-NR_3-SO_2-NR_5-R_6-heterocyclyl; and

-R_4-NR_3-SO_2-NH_2;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_5)_2$;

-CO-$N(R_5)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

Y is -O- or -$S(O)_{0-2}$-;

R_3 is H, C_{1-10} alkyl, or arylalkyl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups; or when R_3 is C_{1-10} alkyl R_3 and R_4 can join together to form a piperidine-ring;

each R_5 is independently H, C_{1-10} alkyl, or C_{2-10} alkenyl;

R_6 is a bond, alkyl, or alkenyl, which may be interrupted by one or more

-O- groups;

R_7 is C_{1-10} alkyl; or when R_3 is C_{1-10} alkyl R_3 and R_7 can join together to form a 5-membered heterocyclic ring;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

19-23 (canceled)

24 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~or salt of claim 11 to the animal~~of the formula (II):



(II)

wherein: **X** is $-CHR_5-$, $-CHR_5$-alkyl-, or $-CHR_5$-alkenyl-;

R_1 is selected from the group consisting of:

$-R_4-NR_3-SO_2-R_6-$alkyl;

$-R_4-NR_3-SO_2-R_6-$alkenyl;

$-R_4-NR_3-SO_2-R_6-$aryl;

$-R_4-NR_3-SO_2-R_6-$heteroaryl;

$-R_4-NR_3-SO_2-R_6-$heterocyclyl;

$-R_4-NR_3-SO_2-R_7$;

$-R_4-NR_3-SO_2-NR_5-R_6$-alkyl;

$-R_4-NR_3-SO_2-NR_5-R_6$-alkenyl;

-R_4-NR_3-SO_2-NR_5-R_6-aryl;

-R_4-NR_3-SO_2-NR_5-R_6-heteroaryl;

-R_4-NR_3-SO_2-NR_5-R_6-heterocyclyl; and

-R_4-NR_3-SO_2-NH_2;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_5)_2$;

-CO-$N(R_5)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

Y is -O- or -$S(O)_{0-2}$-;

R_3 is H, C_{1-10} alkyl, or arylalkyl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups; or when R_3 is $C_{1\text{-}10}$ alkyl R_3 and R_4 can join together to form a piperidine ring;

each R_5 is independently H, $C_{1\text{-}10}$ alkyl, or $C_{2\text{-}10}$ alkenyl;

R_6 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;

R_7 is $C_{1\text{-}10}$ alkyl; or when R_3 is $C_{1\text{-}10}$ alkyl R_3 and R_7 can join together to form a 5-membered heterocyclic ring;

n is 0 to 4; and

each R present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen, and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

25 (new) A method of inducing cytokine biosynthesis in an animal comprising administering a compound selected from the group consisting of

N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;

N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;

N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;

N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;

2-butyl-1-{2-[2-(1,1-dioxidoisothiazolidin-2-yl)ethoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and

N-[10-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,7-dioxadecyl]-5-dimethylaminonaphthalene-1-sulfonamide;

or a pharmaceutically acceptable salt thereof, to the animal in an amount effective for cytokine induction.

26 (new) A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the

group consisting of *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;
2-butyl-1-{2-[2-(1,1-dioxidoisothiazolidin-2-yl)ethoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and
N-[10-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,7-dioxadecyl]-5-dimethylaminonaphthalene-1-sulfonamide;
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

27 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;
N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylmethanesulfonamide;
2-butyl-1-{2-[2-(1,1-dioxidoisothiazolidin-2-yl)ethoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and
N-[10-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,7-dioxadecyl]-5-dimethylaminonaphthalene-1-sulfonamide;
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.